{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:02:25Z","timestamp":1784674945823,"version":"3.55.0"},"reference-count":28,"publisher":"Becaris Publishing Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Major depressive disorder (MDD) is a debilitating illness in which depressive symptoms may persist after treatment. Treatment inertia is the continued use of the same pharmacotherapy regimen when treatment goals are not met. This study assessed the frequency of treatment inertia among adult patients with MDD treated in a real-world setting.\n            <jats:bold>Patients &amp; methods:<\/jats:bold>\n            This was a retrospective, observational study of patients with MDD identified in the Decision Resources Group Real World Evidence US Data Repository from January 2014 to\u00a0June 2018. Patients (\u226518\u00a0years) had an elevated Patient Health Questionnaire-9 (PHQ-9) score (\u22655) following 8\u00a0weeks of stable baseline antidepressant use with\/without mental-health outpatient therapy. Treatment inertia, modification and discontinuation were evaluated over a 16-week follow-up period (timeline based on the APA Practice Guidelines). The primary outcome was the proportion of MDD patients experiencing treatment inertia.\n            <jats:bold>Results:<\/jats:bold>\n            2850 patients (median age, 55\u00a0years; 74% female) met the study criteria. Of these patients, 834 (29%) had study-defined treatment inertia, 1534 (54%) received treatment modification and 482 (17%) discontinued treatment. Use of mirtazapine (Odd ratio [OR]: 0.63; 95% confidence interval [CI]: 0.50\u20130.79), selective serotonin reuptake inhibitors (OR: 0.64; 95% CI: 0.54\u20130.75) or bupropion (OR: 0.71; 95% CI: 0.60\u20130.84) in the baseline period was associated with an increased likelihood of treatment modification versus not receiving treatment with these medications. Frequency of treatment inertia may differ among those who do not have a documented PHQ-9 score.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Effective symptom management is critical for optimal outcomes in MDD. Results demonstrate that treatment inertia is common in MDD despite guidelines recommending treatment modification in patients not reaching remission.\n          <\/jats:p>","DOI":"10.57264\/cer-2023-0091","type":"journal-article","created":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T15:28:33Z","timestamp":1700580513000},"source":"Crossref","is-referenced-by-count":5,"title":["Real-world assessment of treatment inertia in the management of patients treated for major depressive disorder in the USA"],"prefix":"10.57264","volume":"13","author":[{"given":"John J","family":"Sheehan","sequence":"first","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Titusville, NJ\u00a008560, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"LaVallee","sequence":"additional","affiliation":[{"name":"Health Outcomes Research, Decision Resources Group, Boston, MA\u00a002116, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshia","family":"Maughn","sequence":"additional","affiliation":[{"name":"Analytics, Decision Resources Group, Boston, MA\u00a002116, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Balakrishnan","sequence":"additional","affiliation":[{"name":"Analytics, Decision Resources Group, Boston, MA\u00a002116, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline A","family":"Pesa","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Titusville, NJ\u00a008560, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kruti","family":"Joshi","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, LLC, Titusville, NJ\u00a008560, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of California San Francisco, San Francisco, CA\u00a094143, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"key":"e_1_3_7_3_2","unstructured":"National Institute of Mental Health. Major depression. National survey on drug use and health. www.nimh.nih.gov\/health\/statistics\/major-depression.shtml"},{"key":"e_1_3_7_4_2","unstructured":"American Psychiatric Association. Practice guidelines for the treatment of major depressive disorder. https:\/\/psychiatryonline.org\/pb\/assets\/raw\/sitewide\/practice_guidelines\/guidelines\/mdd.pdf"},{"issue":"10100","key":"e_1_3_7_5_2","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S0140-6736(17)32130-X","article-title":"Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"GBD DALYs and Hale Collaborators","year":"2017","unstructured":"GBD DALYs and Hale Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390(10100), 1260\u20131344 (2017).","journal-title":"Lancet"},{"issue":"10","key":"e_1_3_7_6_2","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/archpsyc.64.10.1180","article-title":"The impact of comorbidity of mental and physical conditions on role disability in the US adult household population","volume":"64","author":"Merikangas KR","year":"2007","unstructured":"Merikangas KR, Ames M, Cui L The impact of comorbidity of mental and physical conditions on role disability in the US adult household population. Arch. Gen. Psychiatry 64(10), 1180\u20131188 (2007).","journal-title":"Arch. Gen. Psychiatry"},{"issue":"23","key":"e_1_3_7_7_2","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","article-title":"The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)","volume":"289","author":"Kessler RC","year":"2003","unstructured":"Kessler RC, Berglund P, Demler O The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289(23), 3095\u20133105 (2003).","journal-title":"JAMA"},{"issue":"2","key":"e_1_3_7_8_2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/ijnp\/pyx081","article-title":"Functional recovery in major depressive disorder: providing early optimal treatment for the individual patient","volume":"21","author":"Oluboka OJ","year":"2018","unstructured":"Oluboka OJ, Katzman MA, Habert J Functional recovery in major depressive disorder: providing early optimal treatment for the individual patient. Int. J. Neuropsychopharmacol. 21(2), 128\u2013144 (2018).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"e_1_3_7_9_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jad.2013.10.002","article-title":"Duration of untreated illness and outcomes in unipolar depression: a systematic review and meta-analysis","volume":"152","author":"Ghio L","year":"2014","unstructured":"Ghio L, Gotelli S, Marcenaro M, Amore M, Natta W. Duration of untreated illness and outcomes in unipolar depression: a systematic review and meta-analysis. J. Affect. Disord. 152\u2013154, 45\u201351 (2014).","journal-title":"J. Affect. Disord."},{"issue":"1","key":"e_1_3_7_10_2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jad.2012.07.008","article-title":"The effect of prolonged duration of untreated depression on antidepressant treatment outcome","volume":"145","author":"Bukh JD","year":"2013","unstructured":"Bukh JD, Bock C, Vinberg M, Kessing LV. The effect of prolonged duration of untreated depression on antidepressant treatment outcome. J. Affect. Disord. 145(1), 42\u201348 (2013).","journal-title":"J. Affect. Disord."},{"issue":"3","key":"e_1_3_7_11_2","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1440-1819.2010.02091.x","article-title":"Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder","volume":"64","author":"Okuda A","year":"2010","unstructured":"Okuda A, Suzuki T, Kishi T Duration of untreated illness and antidepressant fluvoxamine response in major depressive disorder. Psychiatry Clin. Neurosci. 64(3), 268\u2013273 (2010).","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"1","key":"e_1_3_7_12_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0165-0327(98)00133-5","article-title":"First admissions for depression: is the \u2018no-treatment interval\u2019 a critical predictor of time to remission?","volume":"54","author":"Gormley N","year":"1999","unstructured":"Gormley N, O'Leary D, Costello F. First admissions for depression: is the \u2018no-treatment interval\u2019 a critical predictor of time to remission? J. Affect. Disord. 54(1\u20132), 49\u201354 (1999).","journal-title":"J. Affect. Disord."},{"issue":"5","key":"e_1_3_7_13_2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/mp.2012.33","article-title":"The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications","volume":"18","author":"Moylan S","year":"2013","unstructured":"Moylan S, Maes M, Wray NR, Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol. Psychiatry. 18(5), 595\u2013606 (2013).","journal-title":"Mol. Psychiatry."},{"key":"e_1_3_7_14_2","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.2147\/NDT.S124277","article-title":"The impact of residual symptoms on relapse and quality of life among Thai depressive patients","volume":"12","author":"Hiranyatheb T","year":"2016","unstructured":"Hiranyatheb T, Nakawiro D, Wongpakaran T The impact of residual symptoms on relapse and quality of life among Thai depressive patients. Neuropsychiatr. Dis. Treat. 12, 3175\u20133181 (2016).","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"3","key":"e_1_3_7_15_2","doi-asserted-by":"crossref","first-page":"OT19037BR2","DOI":"10.4088\/JCP.OT19037BR2","article-title":"Recognizing inadequate response in patients with major depressive disorder","volume":"81","author":"Jackson WC","year":"2020","unstructured":"Jackson WC, Papakostas GI, Rafeyan R, Trivedi MH. Recognizing inadequate response in patients with major depressive disorder. J. Clin. Psychiatry 81(3), OT19037BR2 (2020).","journal-title":"J. Clin. Psychiatry"},{"key":"e_1_3_7_16_2","unstructured":"American Psychiatric Association. Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts. www.apa.org\/depression-guideline\/guideline.pdf"},{"key":"e_1_3_7_17_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12688\/f1000research.10300.1","article-title":"Recent advances in predicting responses to antidepressant treatment","volume":"6","author":"Frodl T","year":"2017","unstructured":"Frodl T. Recent advances in predicting responses to antidepressant treatment. F1000Res. 6, 1\u20136 F1000 Faculty Rev-619 (2017).","journal-title":"F1000Res."},{"issue":"9","key":"e_1_3_7_18_2","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1176\/ajp.2006.163.9.1519","article-title":"A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report","volume":"163","author":"Nierenberg AA","year":"2006","unstructured":"Nierenberg AA, Fava M, Trivedi MH A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am. J. Psychiatry 163(9), 1519\u20131530 (2006).","journal-title":"Am. J. Psychiatry"},{"issue":"11","key":"e_1_3_7_19_2","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush AJ","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163(11), 1905\u20131917 (2006).","journal-title":"Am. J. Psychiatry"},{"issue":"9","key":"e_1_3_7_20_2","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1038\/sj.npp.1301131","article-title":"Report by the ACNP Task Force on response and remission in major depressive disorder","volume":"31","author":"Rush AJ","year":"2006","unstructured":"Rush AJ, Kraemer HC, Sackeim HA Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 31(9), 1841\u20131853 (2006).","journal-title":"Neuropsychopharmacology"},{"key":"e_1_3_7_21_2","unstructured":"US Department of Veterans Affairs. VA\/DoD Clinical Practice Guidelines. www.healthquality.va.gov\/guidelines\/MH\/mdd\/"},{"issue":"9","key":"e_1_3_7_22_2","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/0706743716659417","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments","volume":"61","author":"Kennedy SH","year":"2016","unstructured":"Kennedy SH, Lam RW, McIntyre RS Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can. J. Psychiatry 61(9), 540\u2013560 (2016).","journal-title":"Can. J. Psychiatry"},{"issue":"6","key":"e_1_3_7_23_2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.diabet.2017.06.003","article-title":"Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus","volume":"43","author":"Reach G","year":"2017","unstructured":"Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 43(6), 501\u2013511 (2017).","journal-title":"Diabetes Metab."},{"issue":"11","key":"e_1_3_7_24_2","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.2337\/dc13-0331","article-title":"Clinical inertia in people with Type 2 diabetes: a retrospective cohort study of more than 80,000 people","volume":"36","author":"Khunti K","year":"2013","unstructured":"Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with Type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care 36(11), 3411\u20133417 (2013).","journal-title":"Diabetes Care"},{"key":"e_1_3_7_25_2","unstructured":"DRG. Research and data. https:\/\/decisionresourcesgroup.com\/research-data\/"},{"issue":"9","key":"e_1_3_7_26_2","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke K","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J. Gen. Intern. Med. 16(9), 606\u2013613 (2001).","journal-title":"J. Gen. Intern. Med."},{"issue":"1","key":"e_1_3_7_27_2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/JCP.0000000000001638","article-title":"Early response to antidepressant medications in adults with major depressive disorder: a naturalistic study and odds of remission at 14 weeks","volume":"43","author":"Belanger HG","year":"2023","unstructured":"Belanger HG, Lee C, Poliacoff Z, Gupta CT, Winsberg M. Early response to antidepressant medications in adults with major depressive disorder: a naturalistic study and odds of remission at 14 weeks. J. Clin. Psychopharmacol. 43(1), 46\u201354 (2023).","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"e_1_3_7_28_2","doi-asserted-by":"crossref","first-page":"OT19037BR3","DOI":"10.4088\/JCP.OT19037BR3","article-title":"Inadequate response to treatment in major depressive disorder: augmentation and adjunctive strategies","volume":"81","author":"Rafeyan R","year":"2020","unstructured":"Rafeyan R, Papakostas GI, Jackson WC, Trivedi MH. Inadequate response to treatment in major depressive disorder: augmentation and adjunctive strategies. J. Clin. Psychiatry 81(3), OT19037BR3 (2020).","journal-title":"J. Clin. Psychiatry"},{"issue":"12","key":"e_1_3_7_29_2","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1080\/03007995.2019.1652053","article-title":"Healthcare resource use and cost associated with timing of pharmacological treatment for major depressive disorder in USA: a real-world study","volume":"35","author":"McIntyre RS","year":"2019","unstructured":"McIntyre RS, Prieto R, Schepman P Healthcare resource use and cost associated with timing of pharmacological treatment for major depressive disorder in USA: a real-world study. Curr. Med. Res. Opin. 35(12), 2169\u20132177 (2019).","journal-title":"Curr. Med. Res. Opin."},{"key":"e_1_3_7_30_2","unstructured":"University of Massachusetts Medical School. Therapeutic Class Overview. Serotonin modulators www.medicaid.nv.gov\/Downloads\/provider\/Serotonin_Modulators_2014-0213.pdf"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2023-0091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T11:36:59Z","timestamp":1704454619000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2023-0091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.57264\/cer-2023-0091"],"URL":"https:\/\/doi.org\/10.57264\/cer-2023-0091","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"article-number":"e230091"}}